Hepatitis C virus antigen-antibody combined detection method

Abstract

The invention discloses a method for jointly detecting hepatitis C virus (HCV) antigen-antibody. A monoclonal antibody of an anti-HCV core antigen and a chimeric antigen are coated with enzyme-linked plate to be detected simultaneously, so that the method can shorten the 'window period' of HCV virus detection. Moreover, HCV antibodies in serum and the compatibility with the coated monoclonal antibody can be detected as possible so as to avoid the combination of the chimeric antigen and the monoclonal antibody by modifying HCV overall length core antigen, telescoping non-structural areas and realizing the expression of the chimeric antigen, and the positive detection rate is close to the PCR positive detection rate. The HCV detection method also has the advantages of simple operation, low price, so the method is suitable for promotion and application.

Description

technical field [0001] The invention relates to the technical field of virus detection, in particular to a method for combined detection of hepatitis C virus antigen and antibody. Background technique [0002] Hepatitis C is a global infectious disease caused by hepatitis C virus (Hepatitis C virus, HCV) infection. It is estimated that there are currently 170 million hepatitis C virus-infected people in the world, and the hepatitis C infection rate in my country is about 3.0%. At present, there are at least 40-60 million hepatitis C patients. Among them, 80-85% of the infected patients will develop chronic hepatitis C, and 20% of them will develop liver fibrosis, and finally 4-5% of the patients with liver fibrosis will develop hepatocellular carcinoma, which is very harmful. [0003] At present, there is no specific drug for the treatment of hepatitis C virus, and the development of hepatitis C vaccine is also difficult due to the rapid mutation of HCV, and it is difficult...

AI Technical Summary

Problems solved by technology

Since HCV-RNA appears in the blood of infected persons 6 to 15 days after HCV infection, and reaches a high level before seroconversion, the routine screening of blood donors using this detection technology can greatly reduce the "window period". "The risk of infection, although the method of qualitative or quantitative detection of HCV virions has the characteristics of early, sensitive and specific, but because this technology requires expensive and sophisticated instruments, high experimental skills, expensive reagents, and it is easy to cause cross-contamination. False positives are high, making it difficult to extend to individual blood donors, and its application in developing countries is also largely limited

At present, there is no report about the combined detection of HCV antibody and HCV core antigen, which greatly shortens the "window period" of HCV infection

Images